Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bean Extract-Based Gargle for Efficient Diagnosis of Active COVID-19 Infection Using Rapid Antigen Tests.
Kwon J, Ko E, Cho SY, Lee YH, Jun S, Lee K, Hwang E, Vaidya B, Hwang JH, Hwang JH, Kim N, Song MK, Kim HY, Ito D, Lin Y, Jo E, Yang KE, Chung HC, Cha S, Kim DI, Yi YS, Yun SH, Park SC, Lee S, Choi JS, Kim DS, Kim D. Kwon J, et al. Among authors: chung hc. Microbiol Spectr. 2022 Feb 23;10(1):e0161421. doi: 10.1128/spectrum.01614-21. Epub 2022 Feb 16. Microbiol Spectr. 2022. PMID: 35171037 Free PMC article.
Author's Reply to "Concerns regarding Validity of the Use of Bean Extract-Based Gargle for COVID-19 Diagnosis".
Kwon J, Ko E, Cho SY, Lee YH, Jun S, Lee K, Hwang E, Vaidya B, Hwang JH, Hwang JH, Kim N, Song MK, Kim HY, Ito D, Lin Y, Jo E, Yang KE, Chung HC, Cha S, Kim DI, Yi YS, Yun SH, Park SC, Lee S, Choi JS, Kim DS, Kim D. Kwon J, et al. Among authors: chung hc. Microbiol Spectr. 2022 Aug 31;10(4):e0107022. doi: 10.1128/spectrum.01070-22. Epub 2022 Jul 5. Microbiol Spectr. 2022. PMID: 35862949 Free PMC article. No abstract available.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: chung hc. Invest New Drugs. 2024 May 20. doi: 10.1007/s10637-024-01444-0. Online ahead of print. Invest New Drugs. 2024. PMID: 38767685 No abstract available.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: chung hc. Nat Med. 2024 May 14. doi: 10.1038/s41591-024-02992-x. Online ahead of print. Nat Med. 2024. PMID: 38745009
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
González-Martín A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. González-Martín A, et al. Among authors: chung hc. Gynecol Oncol. 2024 May 7;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Online ahead of print. Gynecol Oncol. 2024. PMID: 38718741
682 results